Anticardiolipin antibody and the development of arterial and venous thrombosis.

系统性红斑狼疮（SLE）和其他胶原蛋白疾病患者抗心磷脂抗体（aCL）的出现与多种临床特征相关，包括动脉和静脉血栓栓塞表现、复发性胎儿丢失和血小板减少。这些症状被称为抗脂质综合征（APS）。我们从APS患者及其动物模型中研究了aCL的特异性，得到了以下结果。1) aCL识别出β 2-糖蛋白I （β 2- gpi）结构的改变。2) β 2- gpi上的表位是通过β 2- gpi与氧取代的固相表面相互作用时发生构象变化来表达的。3)利用APS患者淋巴细胞建立人acl单克隆细胞系。4)氧化脂蛋白，尤其是氧化LDL，依次被β - gpi和aCL靶向。

The appearance of anticardiolipin antibodies (aCL) in patients with systemic lupus erythematosus (SLE) and other collagen diseases is associated with variety of clinical features, including arterial and venous thromboembolic manifestation, recurrent fetal loss and thrombocytopenia. These symptoms called antipholipid syndrome (APS).We investigated the specificity of aCL from patients with APS and from its animal model and obtained following results.1) aCL recognized an altered structure of beta2-glycoprotein I (beta2-GPI) .2) The epitope on beta2-GPI is expressed by a conformational change occurring when beta2-GPI interacts with an oxygen-substituted solid-phase surface.3) Human monoclonal aCL-producing cell lines were established from APS patients' lymphocytes.4) Oxidized lipoproteins, especially oxidized LDL,are sequentially targeted by beta2-GPI and aCL.